De Novo Small Cell Neuroendocrine Carcinoma of the Prostate: Molecular Heterogeneity on Triple-Tracer PET/CT and Its Implications for Personalized Treatment Strategy
Journal of Nuclear Medicine Technology · 09.06.2026 · jnmt.126.272275
DOI: 10.2967/jnmt.126.272275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, online erschienen am 09.06.2026. Verfasst von Rangat Bagasariya und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; and. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; and.
- Homi Bhabha National Institute, Mumbai, India.
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; and drsanb@yahoo.com.
Zitieren
APA
Bagasariya, R., Parghane, R. V., & Basu, S. (2026). De Novo Small Cell Neuroendocrine Carcinoma of the Prostate: Molecular Heterogeneity on Triple-Tracer PET/CT and Its Implications for Personalized Treatment Strategy. Journal of Nuclear Medicine Technology, jnmt.126.272275. https://doi.org/10.2967/jnmt.126.272275
Vancouver
Bagasariya R, Parghane RV, Basu S. De Novo Small Cell Neuroendocrine Carcinoma of the Prostate: Molecular Heterogeneity on Triple-Tracer PET/CT and Its Implications for Personalized Treatment Strategy. Journal of Nuclear Medicine Technology. 2026:jnmt.126.272275. doi:10.2967/jnmt.126.272275
BibTeX
@article{Bagasariya2026,
author = {Bagasariya, Rangat and Parghane, Rahul Vithalrao and Basu, Sandip},
title = {De Novo Small Cell Neuroendocrine Carcinoma of the Prostate: Molecular Heterogeneity on Triple-Tracer PET/CT and Its Implications for Personalized Treatment Strategy},
journal = {Journal of Nuclear Medicine Technology},
year = {2026},
pages = {jnmt.126.272275},
doi = {10.2967/jnmt.126.272275}
}
EUVIMED